-

Crown Bioscience Signals Increased Investment in Digital Transformation with Appointment of New COO

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.

Mr. Gu joins CrownBio from WuXi Nextcode, a global leader in genomic data analysis, where he was general manager for the China business, as well as chief digital officer. At WuXi Nextcode, John spearheaded a block-chain enabled secure mobile health data bank integrating genomic, clinical and behavioral data for precision healthcare. He also led the effort to apply big data and AI technologies to improve medical genomic interpretation accuracy and efficiency and to improve customer experience via digital technologies.

“I am thrilled to welcome John to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “John brings a wealth of experience in global business and operational transformation, and his deep expertise in the growth of technology platforms will be instrumental in helping CrownBio’s global operations evolve and excel, and at the same time develop our innovative digital and in silico preclinical solutions.”

Prior to WuXi Nextcode, Mr. Gu held successive senior technology and operations roles across digital and technology companies, where he successfully led multiple large-scale global IT transformation projects. This includes Alcatel-Lucent, where John led the IT integration and digital transformation across operations in over 140 countries.

“I am delighted to join CrownBio at this point in time,” said John Gu. “Life science is experiencing exponential growth due to recent developments in science and technologies across multiple disciplines. Through enhanced operational excellence, innovation, and digital technologies, we are well poised to continue to deliver value to our customers.”

Mr. Gu holds an MBA from the University of Chicago, an MS in Computer Science from Loyola University of Chicago, and a double-major BS in Computer Science and Electrical Engineering from Shanghai Jiao Tong University.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:

https://www.crownbio.com
https://www.jsrlifesciences.com

Contacts

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com

Crown Bioscience

Details
Headquarters: San Diego, California, USA
CEO: John Gu
Employees: 700+
Organization: PRI

Release Summary
Crown Bioscience Appoints New COO John Gu, Signalling Increased Investment in Digital Transformation

Contacts

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com

Social Media Profiles
More News From Crown Bioscience

JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited

SAN DIEGO--(BUSINESS WIRE)--JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move wi...

Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to e...

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-deriv...
Back to Newsroom